{"id":"https://openalex.org/W2980249347","doi":"https://doi.org/10.1182/blood.v108.11.2669.2669","title":"A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.","display_name":"A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.","publication_year":2006,"publication_date":"2006-11-16","ids":{"openalex":"https://openalex.org/W2980249347","doi":"https://doi.org/10.1182/blood.v108.11.2669.2669","mag":"2980249347"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v108.11.2669.2669","doi":"https://doi.org/10.1182/blood.v108.11.2669.2669","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.2669.2669","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055740968","display_name":"Mikkael Aaron Sekeres","orcid":"https://orcid.org/0000-0003-2009-6524","observed_orcids":["https://orcid.org/0000-0003-2009-6524"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikkael A. Sekeres","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085974329","display_name":"Jaroslaw Pawel Maciejewski","orcid":"https://orcid.org/0000-0002-6837-4346","observed_orcids":["https://orcid.org/0000-0002-6837-4346"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaroslaw P. Maciejewski","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050556099","display_name":"Harry Paul Erba","orcid":"https://orcid.org/0000-0003-1093-2189","observed_orcids":["https://orcid.org/0000-0003-1093-2189"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry Paul Erba","raw_affiliation_strings":["University of Michigan, Ann Arbor, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan, Ann Arbor, MI, USA","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011655907","display_name":"Ronald M. Sobecks","orcid":"https://orcid.org/0000-0003-1608-3261","observed_orcids":["https://orcid.org/0000-0003-1608-3261"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald Sobecks","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082944296","display_name":"Anjali S. Advani","orcid":"https://orcid.org/0000-0003-0015-5902","observed_orcids":["https://orcid.org/0000-0003-0015-5902"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjali Advani","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064219364","display_name":"Julie A. Nichols","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Julie Nichols","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102119494","display_name":"Josephine Chan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Josephine Chan","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112129467","display_name":"Matt E Kalaycio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matt Kalaycio","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5064219364","https://openalex.org/A5102119494"],"corresponding_institution_ids":["https://openalex.org/I1316902750"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.42060281,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"108","issue":"11","first_page":"2669","last_page":"2669"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.010999999940395355,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/arsenic-trioxide","display_name":"arsenic trioxide","score":0.9100000262260437},{"id":"https://openalex.org/keywords/gemtuzumab-ozogamicin","display_name":"gemtuzumab ozogamicin","score":1.0},{"id":"https://openalex.org/keywords/higher-risk-myelodysplastic-syndromes","display_name":"high-risk myelodysplastic syndrome","score":0.9309999942779541},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.8669999837875366},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6700000166893005},{"id":"https://openalex.org/keywords/cd33","display_name":"CD33","score":0.8299999833106995},{"id":"https://openalex.org/keywords/anti-cd33-monoclonal-antibody","display_name":"anti-CD33 monoclonal antibody","score":0.8429999947547913},{"id":"https://openalex.org/keywords/calicheamicin","display_name":"calicheamicin","score":0.8980000019073486},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.49799999594688416},{"id":"https://openalex.org/keywords/cytogenetic-risk","display_name":"cytogenetic risk","score":0.5509999990463257},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C2778623314","wikidata":"https://www.wikidata.org/wiki/Q412685","display_name":"Gemtuzumab ozogamicin","level":5,"score":0.8978947401046753},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8202850818634033},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7024401426315308},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.6530724763870239},{"id":"https://openalex.org/C176290653","wikidata":"https://www.wikidata.org/wiki/Q21114013","display_name":"CD33","level":4,"score":0.5458058714866638},{"id":"https://openalex.org/C2778245361","wikidata":"https://www.wikidata.org/wiki/Q409744","display_name":"Calicheamicin","level":3,"score":0.47892388701438904},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.4776381552219391},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4734453856945038},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.4398265480995178},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4120347201824188},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4053899049758911},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.3905239701271057},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.24730387330055237},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.08301553130149841},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.06828567385673523},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v108.11.2669.2669","doi":"https://doi.org/10.1182/blood.v108.11.2669.2669","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.2669.2669","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2070656041","https://openalex.org/W4254267775","https://openalex.org/W2552228689","https://openalex.org/W2600483298","https://openalex.org/W2599388247","https://openalex.org/W2584937988","https://openalex.org/W2559022709","https://openalex.org/W2530133575","https://openalex.org/W2531227527","https://openalex.org/W94845604"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Bone":[2],"marrow":[3,157],"findings":[4],"in":[5,13,41,47,83,344,491,508,523],"high-risk":[6,86,526],"MDS":[7,87,104,186,218,304,353,376,527],"are":[8,17,30,204],"similar":[9,31],"to":[10,21,32,58,459,476,519],"those":[11,33],"found":[12],"AML.":[14,196,530],"MDS-associated":[15],"myeloblasts":[16],"just":[18],"as":[19,24,175,261],"likely":[20],"express":[22],"CD33":[23],"AML":[25,36,42,101,189,256,308,358,364,405,408],"myeloblasts,":[26],"and":[27,67,70,133,164,237,241,249,270,292,339,366,394,399,503,510],"cytogenetic":[28,227,258],"abnormalities":[29],"of":[34,230,244,299,319,356,456,473,483,488,497],"older":[35],"patients":[37,346,379,463],"(pts).":[38],"Therapies":[39],"effective":[40],"may":[43,71,514],"also":[44],"have":[45,200],"activity":[46],"advanced":[48],"MDS.":[49],"GO":[50,75,134,500],"is":[51,501],"an":[52,321],"anti-CD33":[53],"monoclonal":[54],"antibody":[55],"covalently":[56],"linked":[57],"calicheamicin,":[59],"a":[60,80,153,160,297,381,386,391,411,486,516],"cytotoxic":[61],"agent.":[62],"ATO":[63,121,498],"works":[64],"through":[65],"apoptotic":[66],"pro-differentiating":[68],"mechanisms,":[69],"allow":[72],"for":[73,139,185,188,195,206,303,307,329,446,465],"enhanced":[74],"cytotoxicity.":[76],"Methods:":[77],"We":[78],"conducted":[79],"multicenter":[81],"trial":[82],"pts":[84,199,215,253,274,359,409,444,524],"with":[85,96,225,257,525],"(IPSS":[88],"score":[89],">1.5,":[90],"or":[91,93,100,141,150,420,528],"FAB":[92],"WHO":[94],"classification":[95],">5%":[97],"CD33+":[98,106],"myeloblasts)":[99,107],"arising":[102],"from":[103,115],"(with":[105],"who":[108,146,479],"had":[109,147,217,255,296,380,385,390,396],"not":[110],"received":[111,120,159,275],"previous":[112],"induction":[113],"therapy,":[114],"2/04":[116],"\u2013":[117],"6/06.":[118],"Pts":[119,145,295,478],"(0.25mg/kg":[122],"IV":[123],"d1\u20135":[124],"during":[125],"week":[126,154,167],"1,":[127],"then":[128,165],"twice":[129],"weekly":[130],"weeks":[131],"2\u201312)":[132],"(3mg/m2":[135],"on":[136,152],"day":[137],"8)":[138],"1":[140,317,395],"2":[142,223,326,355,367,378,389,407,472],"12-week":[143,162],"cycles.":[144,327],"stable":[148],"disease":[149,337],"improvement":[151],"12":[155,462],"bone":[156],"biopsy":[158],"second":[161],"cycle,":[163],"another":[166],"24":[168],"biopsy.":[169],"The":[170,208,495],"primary":[171],"endpoint":[172],"was":[173,211],"response":[174,193],"defined":[176,262],"by":[177,263,350,361,369],"the":[178,191,311,351,362,373,403,492],"Modified":[179],"International":[180],"Working":[181],"Group":[182],"(IWG)":[183],"criteria":[184,194],"or,":[187],"patients,":[190],"IWG":[192,352,363,375,404],"Results:":[197],"Twenty-two":[198],"been":[201],"enrolled;":[202],"21":[203,312],"evaluable":[205,445,464],"response.":[207,401],"median":[209,298,487],"age":[210],"69":[212],"years.":[213],"Fourteen":[214],"(64%)":[216],"(4":[219],"RAEB-1,":[220],"8":[221,345,348,357],"RAEB-2,":[222],"CMML-2,)":[224],"IPSS":[226,242],"risk":[228,259],"groups":[229,260],"good":[231],"(2),":[232,240],"intermediate":[233,266],"(6),":[234,422],"poor":[235],"(4)":[236],"no":[238],"growth":[239,279],"classifications":[243],"high":[245],"(5),":[246,248,283,335],"Int-2":[247],"Int-1":[250],"(2).":[251],"Eight":[252],"(36%)":[254],"CALGB":[264],"8461:":[265],"(4),":[267,424],"adverse":[268],"(3),":[269,285,427],"unknown":[271],"(1).":[272,294,441],"Fifteen":[273],"prior":[276],"therapies,":[277],"including":[278],"factors":[280],"(10),":[281],"5-azacytidine":[282],"hydroxyurea":[284],"prednisone":[286],"(1),":[287,289,291,429,432,435,437,439],"anagrelide":[288],"thalidomide":[290],"lenalidomide":[293],"15%":[300],"blasts:":[301],"11.5%":[302],"pts;":[305],"43.5%":[306],"pts.":[309],"Of":[310,442,461],"pts,":[313],"11":[314],"(52%)":[315],"completed":[316,325,480],"cycle":[318],"therapy;":[320],"additional":[322],"5":[323],"(24%)":[324],"Reasons":[328],"discontinuing":[330],"therapy":[331,484,522],"included:":[332],"withdrawing":[333],"consent":[334],"progressive":[336],"(7),":[338],"toxicity":[340],"(4).":[341],"Responses":[342],"occurred":[343],"(38%):":[347],"(38%)":[349],"criteria;":[354,365],"(25%)":[360],"(9%)":[368],"both":[370,397],"criteria.":[371],"Using":[372,402],"modified":[374],"criteria,":[377],"partial":[382,412],"remission,":[383],"3":[384],"neutrophil":[387,400],"response,":[388,393],"platelet":[392,398],"Criteria,":[406],"achieved":[410],"remission.":[413],"Grade3/4":[414],"non-hematologic":[415],"toxicities":[416],"included":[417],"neutropenic":[418],"fever":[419],"infection":[421],"fatigue":[423],"pulmonary":[425],"complications":[426],"hepatotoxicity":[428],"renal":[430],"failure":[431],"prolonged":[433],"QTc":[434],"nausea":[436],"epistaxis":[438],"hypoxia":[440],"20":[443],"6":[447],"month":[448],"survival,":[449,467],"15":[450],"(75%)":[451],"were":[452,470],"alive,":[453,471],"7":[454],"(47%)":[455],"whom":[457,474],"responded":[458,475],"treatment.":[460,477],"1-year":[466],"4":[468],"(33%)":[469],"two":[481],"cycles":[482],"spent":[485],"13":[489],"days":[490],"hospital.":[493],"Conclusion:":[494],"combination":[496,513],"+":[499],"well-tolerated":[502],"yields":[504],"hematologic":[505],"responses,":[506],"particularly":[507],"neutrophils":[509],"platelets.":[511],"This":[512],"be":[515],"viable":[517],"alternative":[518],"high-dose,":[520],"inpatient":[521],"secondary":[529]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2019-10-18T00:00:00"}